| Hazard Information | Back Directory | [Description]
Telisotuzumab vedotin (Teliso-V) is an antibody drug conjugate that targets the
MET receptor. | [Uses]
Telisotuzumab vedotin (ABBV-399) is an antibody-drug conjugate (ADCs) targeting c-Met. Telisotuzumab vedotin consists of Monomethyl Auristatin E (MMAE), Telisotuzumab antibody and a cleavable mc-val-cit-PABC type linker. Telisotuzumab vedotin can be used to study non-small cell lung cancer expressing c-Met protein[1][2]. | [Clinical Use]
In the first in-human phase I trial for Teliso-V, NSCLC patients with
MET-overexpressing tumors received monotherapy. The results of this innovative
trial indicated favorable safety and tolerability responses and also showed promising
antitumor activity in NSCLC patients with MET overexpression. | [References]
[1] Strickler JH, et al. First-in-Human Phase I, Dose-Escalation and -Expansion Study of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, in Patients With Advanced Solid Tumors. J Clin Oncol. 2018 Nov 20;36(33):3298-3306. DOI:10.1200/JCO.2018.78.7697
[2] Camidge D R, et al. Phase Ib study of telisotuzumab vedotin in combination with erlotinib in patients with c-met protein–expressing non–small-cell lung cancer. Journal of Clinical Oncology, 2023, 41(5): 1105-1115. DOI:10.1200/JCO.22.00739 |
|
| Company Name: |
bioleaper
|
| Tel: |
4000880777 17585207275 |
| Website: |
www.bioleaper.com/ |
|